Baidu
map

将PRO纳入心衰患者预后评估:来自GISSI-HF研究的推荐

2020-02-18 BioMed数据坊 BioMed数据坊

患者报告结局(PRO)可反应心力衰竭患者自身状况,并为预后提供重要信息,然而PRO尚未作为临床常规资料进行收集。为了探讨PRO是否应该纳入心力衰竭患者的预后评估,意大利心肌梗死与心力衰竭生存注册研究(GISSI-HF)研究组采用前瞻性队列研究,对符合纳入标准的心力衰竭患者随访3.3年,从而评价心力衰竭疾病特异性PRO量表之一的堪萨斯城心肌病问卷(KCCQ)对心力衰竭患者死亡和再住院的预测价值,以对

患者报告结局(PRO)可反应心力衰竭患者自身状况,并为预后提供重要信息,然而PRO尚未作为临床常规资料进行收集。

为了探讨PRO是否应该纳入心力衰竭患者的预后评估,意大利心肌梗死与心力衰竭生存注册研究(GISSI-HF)研究组采用前瞻性队列研究,对符合纳入标准的心力衰竭患者随访3.3年,从而评价心力衰竭疾病特异性PRO量表之一的堪萨斯城心肌病问卷(KCCQ)对心力衰竭患者死亡和再住院的预测价值,以对PRO的应用提供依据。

该研究的研究对象来源于83个意大利心脏病中心,共1465例患者。纳入标准为诊断为慢性心力衰竭、NYHA II-III级、冠状动脉和非冠状动脉病因的门诊患者。由护理人员收集患者基线KCCQ,并对其死亡和再住院情况进行随访。采用Cox比例风险回归模型探讨PRO对死亡和再住院的影响。

结果表明,与理想KCCQ得分(>75)相比,低分值KCCQ<25)可预测死亡(1.8595%CI1.16-2.95)(Fig1)。而KCCQ对再住院并无预测作用。NYHA IIIII级的患者进行比较,两组患者KCCQ与结局关系的差异具有统计学意义(Table 1)。

 

Fig 1 Coxproportional hazards adjust survival curves at 3.3 years

Table 1 Mortalityand all hospital admission by NYHA class and KCCQ scores

基于研究中KCCQ对心力衰竭患者死亡的独立预测作用,研究人员建议将KCCQ作为临床心力衰竭患者管理和预后评价的常规指标。

原始出处:

Should patients perception of health status be integrated in theprognostic assessment of heart failure patients? A prospective study. Qual LifeRes, 2014, 23(1). DOI10.1007/s11136-013-0468-8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1743551, encodeId=ceeb1e435517e, content=<a href='/topic/show?id=89691002006b' target=_blank style='color:#2F92EE;'>#预后评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100200, encryptionId=89691002006b, topicName=预后评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4335139306, createdName=yeye5224624, createdTime=Thu Nov 12 23:46:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649438, encodeId=389d1649438ab, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Sep 01 21:46:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373472, encodeId=095913e347233, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602237, encodeId=6330160223e77, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692109, encodeId=eff816921090c, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 01 01:46:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1743551, encodeId=ceeb1e435517e, content=<a href='/topic/show?id=89691002006b' target=_blank style='color:#2F92EE;'>#预后评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100200, encryptionId=89691002006b, topicName=预后评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4335139306, createdName=yeye5224624, createdTime=Thu Nov 12 23:46:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649438, encodeId=389d1649438ab, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Sep 01 21:46:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373472, encodeId=095913e347233, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602237, encodeId=6330160223e77, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692109, encodeId=eff816921090c, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 01 01:46:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
    2020-09-01 nymo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1743551, encodeId=ceeb1e435517e, content=<a href='/topic/show?id=89691002006b' target=_blank style='color:#2F92EE;'>#预后评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100200, encryptionId=89691002006b, topicName=预后评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4335139306, createdName=yeye5224624, createdTime=Thu Nov 12 23:46:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649438, encodeId=389d1649438ab, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Sep 01 21:46:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373472, encodeId=095913e347233, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602237, encodeId=6330160223e77, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692109, encodeId=eff816921090c, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 01 01:46:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1743551, encodeId=ceeb1e435517e, content=<a href='/topic/show?id=89691002006b' target=_blank style='color:#2F92EE;'>#预后评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100200, encryptionId=89691002006b, topicName=预后评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4335139306, createdName=yeye5224624, createdTime=Thu Nov 12 23:46:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649438, encodeId=389d1649438ab, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Sep 01 21:46:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373472, encodeId=095913e347233, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602237, encodeId=6330160223e77, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692109, encodeId=eff816921090c, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 01 01:46:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
    2020-02-20 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1743551, encodeId=ceeb1e435517e, content=<a href='/topic/show?id=89691002006b' target=_blank style='color:#2F92EE;'>#预后评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100200, encryptionId=89691002006b, topicName=预后评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4335139306, createdName=yeye5224624, createdTime=Thu Nov 12 23:46:00 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649438, encodeId=389d1649438ab, content=<a href='/topic/show?id=081a16e10e8' target=_blank style='color:#2F92EE;'>#SSI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16710, encryptionId=081a16e10e8, topicName=SSI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=586523824746, createdName=nymo, createdTime=Tue Sep 01 21:46:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373472, encodeId=095913e347233, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602237, encodeId=6330160223e77, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 20 03:46:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692109, encodeId=eff816921090c, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 01 01:46:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]

相关资讯

科普:三分钟告诉你患者报告结局(PRO)是什么

在临床研究中,通过测评患者对自身疾病症状及其对日常生活所造成的影响所持的态度,来决定治疗方案以及作为评价疗效的工具已经越来越普遍。临床研究领域关键人物也开始认识到了PRO测评日益增长的价值。2006年2月美国FDA(Foodand Drug Administration)发布了关于PRO应用于新药研制和疗效评价的指南草案。意味着PRO正成为评价疗效和药物安全性的重要组成部分。而患者也终于能够真

J Clin Periodontol:牙周健康状况与患者报告结果的关系

本文旨在探讨牙周状况与患者报告结果(PROs)之间的关联,研究在非专科的普通牙科诊所的患者中展开。

HIV病毒抑制剂PRO 140的研究

PRO 140是CytoDyn公司开发的一种新型人源化CCR5单克隆抗体。在PRO 140与现有ART一起皮下注射一周后,病人的平均病毒载量从平均基线病毒载量下降约97%。该试验达到了其主要疗效终点:在一周治疗期结束时,HIV-1 RNA病毒载量降低显著。

PRO专题:新药临床试验要尊重患者感受——Our Health,Our Care,Our Say

近年来,在临床研究中,通过测评患者对自身疾病症状及其对日常生活所造成的影响所持的态度,来决定治疗方案以及作为评价疗效的工具已经越来越普遍。临床研究领域关键人物也开始认识到了患者报告临床结局(patient reported outcome,PRO)测评日益增长的价值。2006年2月美国FDA(Food and Drug Administration)发布了关于PRO应用于新药研制和疗效评价的指南草

Baidu
map
Baidu
map
Baidu
map